In addition to treating imatinib-resistant CML, the new generation BCR-ABL inhibitors developed later on, such as dasatinib and nilotinib, have also been approved to manage scleroderma and SSc [2,20]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.